They used the immunoligand fused with the NKG2D-specific ligand ULBP2 to activate the receptor NKG2D and obtained high anticancer efficacy in the mouse model by inhibiting tumor development in vitro and by increasing cancer cell lysis [119]. Here, KLRK1 is linked to neoplasm.